Byline: Stacy M. Brown NNPA Newswire Senior National Correspondent @StacyBrownMedia The agency announced in a news release that they also would shorten the time between the completion of primary vaccination of the Pfizer-BioNTech COVID-19 Vaccine and a booster dose to at least five months. The FDA said it would allow for a third primary series dose for certain immunocompromised children ages 5 through 11. (Pfizer) The U.S. Food and Drug Administration amended the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to expand the use of a single booster dose to include use in individuals from 12 to 15.
